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The article on antiplatelet drug resistance by
Drs. Burns, Mooss, and Hilleman1 was an
excellent, yet cautionary, review that had several
points that we feel deserve comment.  First, the
authors included a point-of-care measure of
platelet function that could be more completely
explained—the VerifyNow instrument
(Accumetrics, San Diego, CA).  This assay is for
three types of platelet inhibition:  aspirin
mediated inhibition, P2Y12 (thienopyridine)
receptor inhibition, and glycoprotein IIb/IIIa
receptor inhibition.  Resistance to drugs that act
through these pathways is measured through
three different cartridges that can all be used in
the VerifyNow device and are approved by the
United States Food and Drug Administration.2
The aspirin assay uses an arachidonic acid
agonist to activate platelets.  Through light
transmittance, the device then measures the
amount of platelet aggregation that occurs and
reports the result as an aspirin responsive unit
(ARU).  The interpretation of the result is based
on an assigned cutoff (< 550 units indicates
platelet inhibition consistent with aspirin is
present, ≥ 550 units indicates platelet inhibition
consistent with aspirin is not present).  In
contrast to the information provided in the
article by Dr. Burns and his colleagues,1 this
device has been compared with optical aggre-
gometry.  The correlation coefficient for the
VerifyNow aspirin cartridge was excellent when
compared with epinephrine-induced platelet
aggregation measured by the Chrono-Log optical
Aggregometer (Chrono-Log Corp., Havertown,
PA) (r=0.902).3 Furthermore, the P2Y12
(thienopyridine) assay is made to have a greater
specificity for the P2Y12 rather than P2Y1 receptor.
It accomplishes this by using prostaglandin E1
added to adenosine 5′-diphosphate.  This assay
incorporates baseline platelet function and the
P2Y12 reaction units to provide a percentage of
platelet inhibition consistent with thienopyridines
such as clopidogrel.
Since clinical trials have clearly correlated
antiplatelet resistance to adverse outcomes, we
feel that this information could be valuable in
practitioners’ hands in patient-specific scenarios.
For example, in a patient with aspirin resistance,
alternate pharmacologic antiplatelet strategies
such as thienopyridines or higher doses of
aspirin4 may be considered.  In addition, it may
be helpful to measure the effectiveness of
clopidogrel in patients concomitantly receiving a
cytochrome P450 3A4 inhibitor.5–7 Recent
guidelines have also incorporated a recommen-
dation to increase the dose of clopidogrel to 150
mg/day if less than 50% inhibition of platelet
aggregation is demonstrated after high-risk
percutaneous coronary intervention.8
Although these clinical management strategies
have yet to be clinically validated, the potential
adverse outcome of platelet resistance to anti-
platelet therapy is concerning.  As a profession
that thrives on therapeutic drug monitoring,
pharmacists should embrace technology that
allows us to further manage our patient’s drug
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regimens.  Of course this will require investing in
the resources to validate the utility of the assay in
order to determine the clinically meaningful
scenarios in which antiplatelet drug therapy
should be adjusted.
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Authors’ Reply
The authors appreciate the insightful comments
of Drs. Dorsch and Dunn and offer no further
comments.
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